Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclophosphamide | 3 | 2025 | 59 | 1.170 |
Why?
|
| Doxorubicin | 3 | 2025 | 97 | 1.120 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1019 | 0.930 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 3 | 2011 | 11 | 0.870 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 164 | 0.800 |
Why?
|
| DNA Methylation | 1 | 2025 | 403 | 0.710 |
Why?
|
| Fibroblasts | 10 | 2011 | 281 | 0.620 |
Why?
|
| Hippocampus | 2 | 2019 | 594 | 0.550 |
Why?
|
| Biomedical Engineering | 1 | 2017 | 12 | 0.540 |
Why?
|
| Gene Expression Regulation | 4 | 2019 | 1070 | 0.460 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 200 | 0.430 |
Why?
|
| DNA, Mitochondrial | 3 | 2009 | 191 | 0.430 |
Why?
|
| Inflammation | 1 | 2019 | 758 | 0.400 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 196 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2015 | 243 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 299 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 220 | 0.390 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1003 | 0.390 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 105 | 0.380 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 590 | 0.360 |
Why?
|
| Cognition | 1 | 2015 | 473 | 0.340 |
Why?
|
| Melanoma | 2 | 2009 | 110 | 0.320 |
Why?
|
| DNA | 6 | 1995 | 592 | 0.310 |
Why?
|
| Gene Expression | 2 | 2011 | 701 | 0.290 |
Why?
|
| DNA Damage | 4 | 2009 | 356 | 0.260 |
Why?
|
| Gene Deletion | 3 | 2008 | 168 | 0.260 |
Why?
|
| Thymine | 3 | 1992 | 25 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 178 | 0.240 |
Why?
|
| Rats | 2 | 2025 | 3735 | 0.200 |
Why?
|
| Luteinization | 1 | 2002 | 2 | 0.190 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 11 | 0.190 |
Why?
|
| Ribonucleoproteins | 1 | 2002 | 31 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2002 | 32 | 0.190 |
Why?
|
| Fertilization in Vitro | 1 | 2002 | 57 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 291 | 0.190 |
Why?
|
| Granulosa Cells | 1 | 2002 | 44 | 0.180 |
Why?
|
| Phosphoranes | 1 | 2021 | 3 | 0.180 |
Why?
|
| Rubidium | 1 | 2021 | 6 | 0.180 |
Why?
|
| Imines | 1 | 2021 | 9 | 0.180 |
Why?
|
| Simian virus 40 | 6 | 1997 | 35 | 0.180 |
Why?
|
| Aging | 2 | 2008 | 783 | 0.180 |
Why?
|
| Coordination Complexes | 1 | 2021 | 28 | 0.170 |
Why?
|
| Animals | 5 | 2025 | 16992 | 0.160 |
Why?
|
| Female | 6 | 2025 | 24698 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 1997 | 20 | 0.150 |
Why?
|
| Ruthenium | 1 | 2019 | 16 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 71 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 49 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 80 | 0.140 |
Why?
|
| Chemokines | 1 | 2019 | 96 | 0.140 |
Why?
|
| Telomere | 2 | 1996 | 59 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2019 | 2157 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2011 | 986 | 0.130 |
Why?
|
| Gold | 1 | 2019 | 156 | 0.130 |
Why?
|
| Protein Binding | 2 | 2011 | 1082 | 0.130 |
Why?
|
| Humans | 18 | 2021 | 43102 | 0.130 |
Why?
|
| Cell Line | 5 | 2009 | 1410 | 0.130 |
Why?
|
| Mice | 3 | 2025 | 6644 | 0.120 |
Why?
|
| Mentors | 1 | 2017 | 145 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 532 | 0.120 |
Why?
|
| RNA | 2 | 1995 | 266 | 0.120 |
Why?
|
| Apoptosis | 2 | 2009 | 1568 | 0.120 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 30 | 0.120 |
Why?
|
| Schools | 1 | 2017 | 283 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1996 | 165 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 81 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2021 | 346 | 0.110 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 126 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1766 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 1995 | 161 | 0.100 |
Why?
|
| Cell Transformation, Viral | 3 | 1997 | 24 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2015 | 373 | 0.090 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 40 | 0.090 |
Why?
|
| Melanins | 1 | 1992 | 42 | 0.090 |
Why?
|
| Age Factors | 1 | 2015 | 1154 | 0.090 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2011 | 18 | 0.090 |
Why?
|
| Purines | 1 | 2011 | 40 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 28 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 561 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 56 | 0.090 |
Why?
|
| Students | 1 | 2017 | 626 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2015 | 561 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 296 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2011 | 1621 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2002 | 1271 | 0.080 |
Why?
|
| Sunlight | 1 | 2009 | 48 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 90 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 159 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 317 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 652 | 0.060 |
Why?
|
| Phenotype | 1 | 2008 | 780 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1455 | 0.050 |
Why?
|
| Bone Marrow | 2 | 1995 | 35 | 0.050 |
Why?
|
| Transfection | 2 | 2002 | 532 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2676 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 68 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 1997 | 1542 | 0.050 |
Why?
|
| Hydrolases | 1 | 2002 | 15 | 0.050 |
Why?
|
| Okadaic Acid | 1 | 2002 | 16 | 0.050 |
Why?
|
| alpha-Galactosidase | 1 | 2002 | 4 | 0.050 |
Why?
|
| Acid Phosphatase | 1 | 2002 | 23 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 37 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 21 | 0.050 |
Why?
|
| Ceramides | 1 | 2002 | 44 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 256 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 296 | 0.040 |
Why?
|
| Lysosomes | 1 | 2002 | 86 | 0.040 |
Why?
|
| Base Sequence | 4 | 1996 | 983 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 157 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 2853 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 278 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 241 | 0.040 |
Why?
|
| Cell Line, Transformed | 3 | 1997 | 95 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 506 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 384 | 0.040 |
Why?
|
| Angiogenic Proteins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2021 | 570 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1997 | 199 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 968 | 0.040 |
Why?
|
| Adult | 2 | 2008 | 13872 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1995 | 50 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 347 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 655 | 0.030 |
Why?
|
| Adolescent | 1 | 2008 | 6081 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1989 | 460 | 0.030 |
Why?
|
| Karyotyping | 2 | 1994 | 45 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 945 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 109 | 0.030 |
Why?
|
| Aged | 1 | 2008 | 8214 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1604 | 0.030 |
Why?
|
| Male | 2 | 2019 | 23409 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1993 | 28 | 0.030 |
Why?
|
| Osmium Tetroxide | 2 | 1990 | 2 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1993 | 81 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1995 | 883 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1992 | 6 | 0.020 |
Why?
|
| Middle Aged | 1 | 2008 | 12222 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1992 | 68 | 0.020 |
Why?
|
| DNA Probes | 1 | 1992 | 32 | 0.020 |
Why?
|
| Free Radicals | 1 | 1992 | 70 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1992 | 37 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 150 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1992 | 87 | 0.020 |
Why?
|
| Antibodies | 1 | 1992 | 144 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 311 | 0.020 |
Why?
|
| Thymine Nucleotides | 1 | 1990 | 4 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1989 | 9 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1989 | 9 | 0.020 |
Why?
|
| Bacteriophage phi X 174 | 1 | 1989 | 11 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1989 | 76 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 306 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2009 | 67 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 1989 | 206 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1989 | 458 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 457 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1989 | 311 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 800 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 1996 | 7 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 704 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 58 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 21 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1997 | 150 | 0.010 |
Why?
|
| Telomerase | 1 | 1996 | 42 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 61 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1994 | 20 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1994 | 53 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 294 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1993 | 17 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1996 | 220 | 0.010 |
Why?
|
| Luciferases | 1 | 1993 | 71 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 455 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 518 | 0.010 |
Why?
|